Home
About Us
Our Approach
Our Team
Board
Pipeline
News
Honor
Careers
Collaboration
Investor Relations
Disclosure
Contact IR
Contact
中文
ENG
Home
About us
Our Approach
Our Team
Board
Pipeline
News
Honor
Careers
Collaboration
Investor Relations
Disclosure
Contact IR
Contact
CN
TOGETHER,WE SEARCH FOR THE CURE
TOGETHER,WE SEARCH FOR THE CURE
Discover More
80余名
科研人员
40余项
PCT专利
23项
新药专利
ABOUT
TYK Medicines
Focus on new drug research and development
Together, we search for the cure.
Discover More
NEWS
TYK Medicines’ New Drug for Brain Metastasis of Lung Cancer, Asandeutertinib, Has Marketing Application Accepted and Granted Priority Review
Discover More
ESMO 2025 || TYK Medicines Releases Positive Clinical Data on Multiple CDK Inhibitors
Discover More
TYK Medicines, Inc.’s EGFR-Targeted Innovative Drug Asandeutertinib Demonstrates Excellent Efficacy in NSCLC Patients with Brain Metastases — Interim Results from the ESAONA Pivotal Study Announced at WCLC 2025
Discover More
RESEARCH
An innovative biotechnology company focusing on the research and development of innovative drugs
Discover More
